A
Avi Schroeder
Researcher at Technion – Israel Institute of Technology
Publications - 89
Citations - 8391
Avi Schroeder is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Liposome & Cancer. The author has an hindex of 34, co-authored 78 publications receiving 6588 citations. Previous affiliations of Avi Schroeder include Massachusetts Institute of Technology & University of Utah.
Papers
More filters
Journal ArticleDOI
Treating metastatic cancer with nanotechnology
Avi Schroeder,Daniel A. Heller,Monte M. Winslow,Monte M. Winslow,James E. Dahlman,George W. Pratt,Robert Langer,Tyler Jacks,Daniel G. Anderson +8 more
TL;DR: This Review highlights the research, opportunities and challenges for integrating engineering sciences with cancer biology and medicine to develop nanotechnology-based tools for treating metastatic disease.
Journal ArticleDOI
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Gaurav Sahay,William Querbes,Christopher A. Alabi,Ahmed A. Eltoukhy,Sovan Sarkar,Christopher Zurenko,Emmanouil D. Karagiannis,Kevin T. Love,Delai Chen,Roberto Zoncu,Yosef Buganim,Avi Schroeder,Robert Langer,Daniel G. Anderson +13 more
TL;DR: In this paper, the authors examined cellular uptake of siRNA delivered in lipid nanoparticles (LNPs) using cellular trafficking probes in combination with automated high-throughput confocal microscopy as well as defined perturbations of cellular pathways paired with systems biology approaches to uncover protein-protein and protein-small molecule interactions.
Journal ArticleDOI
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight
James E. Dahlman,Carmen M. Barnés,Omar F. Khan,Aude Thiriot,Siddharth Jhunjunwala,Taylor E. Shaw,Yiping Xing,Hendrik B. Sager,Gaurav Sahay,Lauren Speciner,Andrew Bader,Roman L. Bogorad,Hao Yin,Tim Racie,Yizhou Dong,Shan Jiang,Danielle Seedorf,Apeksha Dave,Kamaljeet Singh Sandhu,Matthew J. Webber,Tatiana Novobrantseva,Vera M. Ruda,Abigail K. R. Lytton-Jean,Christopher G. Levins,Brian T. Kalish,Dayna K. Mudge,Mario F. Perez,Ludmila Abezgauz,Partha Dutta,Lynelle P. Smith,Klaus Charisse,Mark W. Kieran,Kevin Fitzgerald,Matthias Nahrendorf,Dganit Danino,Rubin M. Tuder,Ulrich H. von Andrian,Akin Akinc,Dipak Panigrahy,Avi Schroeder,Victor Koteliansky,Robert Langer,Daniel G. Anderson +42 more
TL;DR: These nanoparticles mediate the most durable non-liver silencing reported so far and facilitate the delivery of siRNAs that modify endothelial function in mouse models of vascular permeability, emphysema, primary tumour growth and metastasis.
Journal ArticleDOI
Lipid-based nanotherapeutics for siRNA delivery
TL;DR: The size of the carrier is important as carriers <100 nm in diameter have been reported to have higher accumulation levels in tumours, hepatocytes and inflamed tissue, whereas larger particles tend to be taken up by Kupffer cells or other components of the reticuloendothelial system (RES).
Journal ArticleDOI
Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes
TL;DR: It is suggested that the mechanism of release may involve formation and collapse of small gas nuclei in the hydrophobic region of the lipid bilayer during exposure to LFUS, thereby inducing the formation of transient pores through which drugs are released.